On Aug. 20, 2020, Oragenics and Avid Bioservices announced a process development and drug substance manufacturing agreement. Avid will provide Oragenics with analytical method development, process development and drug substance manufacturing services to support development of Oragenicsﾒ novel SARS CoV-2 (COVID-19) spike protein vaccine candidate, Terra CoV-2.